https://openbell.ai/ 2026-11-06T08:44:17.741Z hourly 1.0 https://openbell.ai/support 2026-11-06T08:44:17.741Z monthly 0.7 https://openbell.ai/privacy 2026-11-06T08:44:17.741Z monthly 0.5 https://openbell.ai/terms 2026-11-06T08:44:17.741Z monthly 0.5 https://openbell.ai/feed.json 2026-11-06T08:44:17.741Z hourly 0.8 https://openbell.ai/news/2914:1793953913000 2026-11-06T08:31:53.000Z daily 0.9 https://cdn.brandfetch.io/2914/w/400/h/400?c=1idopYfmtR7ZKg8QMud Russian Government Places Japan Tobacco Assets Under Temporary Administration Russian President Vladimir Putin ordered Japan Tobacco’s Russian assets, including four factories, placed under the temporary administration of a local company. The move comes amid growing pressure from Moscow on Japan and Western countries over their support for Ukraine. The article reports no financial figures or stock-price impact. https://openbell.ai/news/OLE:1793952338000 2026-11-06T08:05:38.000Z daily 0.9 https://cdn.brandfetch.io/OLE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Deoleo Enters Binding Agreement to Sell Deoleo Holding to Acesur and Dcoop Deoleo signed a binding agreement to sell its main operating subsidiary, Deoleo Holding, to Spanish competitors Acesur and Dcoop. The transaction values the subsidiary at €520 million and covers a 91.99% stake, potentially rising to 100% depending on other shareholders’ participation. Deoleo expects to receive approximately €190 million to €200 million for its directly held 50.99% stake, subject to final adjustments. The deal would give Acesur and Dcoop indirect control of the business and reshape Spain’s olive oil sector. https://openbell.ai/news/HIK:1793952280000 2026-11-06T08:04:40.000Z daily 0.9 https://cdn.brandfetch.io/HIK/w/400/h/400?c=1idopYfmtR7ZKg8QMud SG Holding Increases Tender Offer Price for Haiki+ SG Holding, promoter of the tender offer for EGM-listed Haiki+ S.p.A., raised its offer price from €0.90 to €1.11 per share, an increase of 23.33%. The acceptance period has been extended to November 13, 2026, as the acquisition process continues. https://openbell.ai/news/ALTHE:1793952214000 2026-11-06T08:03:34.000Z daily 0.9 https://cdn.brandfetch.io/ALTHE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Theraclion Obtains FDA Authorization for Sonovein® Theraclion received FDA authorization for its Sonovein® system, which uses high-intensity focused ultrasound to treat varicose veins without incisions or anesthesia. The authorization allows the company to bring its echotherapy technology to U.S. hospitals and clinical treatment centers. The article reports no financial figures or stock-price impact. https://openbell.ai/news/VIRO:1793952199000 2026-11-06T08:03:19.000Z daily 0.9 https://cdn.brandfetch.io/VIRO/w/400/h/400?c=1idopYfmtR7ZKg8QMud ViroGates Reports Interim Results for Q1-Q3 2026 ViroGates reported revenue of DKK 6.2 million for the first nine months of 2026, up 75% year over year, largely due to a minimum-order delivery from U.S. partner suPARbio in Q2; Q3 revenue was DKK 1.1 million. The company maintained its full-year guidance of DKK 6.5–8 million in revenue and an EBIT loss of DKK 10–12 million. ViroGates is shifting from a sales-driven model toward business development focused on larger, scalable partnerships, reviewing its partner portfolio and planning to replace its “recurring customers” KPI with revenue reporting by product and geography from 2027. https://openbell.ai/news/TPG0:1793952177000 2026-11-06T08:02:57.000Z daily 0.9 https://cdn.brandfetch.io/TPG0/w/400/h/400?c=1idopYfmtR7ZKg8QMud The Platform Group SE & Co. KGaA Reports Nine-Month 2026 Financial Results and Reaffirms Guidance The Platform Group SE & Co. KGaA reported nine-month 2026 GMV of EUR 1,076.9 million, up from EUR 902.1 million a year earlier, and net revenue of EUR 622.7 million, compared with EUR 531.6 million. It cited strong organic growth across 26 industries and said its partner network had grown to more than 17,800. The company reaffirmed 2026 guidance of EUR 1.7 billion in GMV, at least EUR 1.0 billion in net revenue, and adjusted EBITDA of EUR 70 million to EUR 80 million. https://openbell.ai/news/CANDLE.B:1793952177000 2026-11-06T08:02:57.000Z daily 0.9 https://cdn.brandfetch.io/CANDLE.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud Candles Scandinavia Reports Third Quarter 2026 Financial Results Candles Scandinavia AB reported EBITDA of SEK 13 million in the third quarter of 2026, compared with a loss of SEK 3.6 million in the same quarter a year earlier. The results indicate a year-over-year turnaround in operating performance. https://openbell.ai/news/WPTG.B:1793952162000 2026-11-06T08:02:42.000Z daily 0.9 https://cdn.brandfetch.io/WPTG.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud White Pearl Technology Group Reports Record Q3 2026 Revenue White Pearl Technology Group reported record Q3 2026 revenue of SEK 179.1 million, up 36.5% year over year, while EBITDA increased 9.5% to SEK 31.3 million. For the first nine months, revenue rose 32.7% to SEK 482.9 million and EBITDA was SEK 84.8 million. AI and Platforms grew to 27% of Q3 revenue, compared with 20% in Q1. The company is focusing on integrating acquisitions, cross-selling and improving cash generation, and said Aixia is now fully integrated. https://openbell.ai/news/BMC:1793952162000 2026-11-06T08:02:42.000Z daily 0.9 https://cdn.brandfetch.io/BMC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brock Milton Capital Reports Q3 2026 Interim Results Brock Milton Capital’s managed assets rose 7.4% year over year to SEK 21.7 billion in Q3 2026. Quarterly operating profit and earnings per share declined, which management attributed to higher growth-related expenses. All four of the company’s funds were added to SPP’s regular selection range, while its global small-cap fund performed strongly in the first nine months of the year. https://openbell.ai/news/EQL:1793952150000 2026-11-06T08:02:30.000Z daily 0.9 https://cdn.brandfetch.io/EQL/w/400/h/400?c=1idopYfmtR7ZKg8QMud EQL Pharma Reports Q2 2026/2027 Financial Results EQL Pharma reported a rebound in sales and EBITDA in the second quarter of fiscal 2026/2027, supported by temporary demand following stock-outs and a milestone payment related to Mellozzan. Write-downs weighed on gross margin. Management maintained its full-year growth guidance of 15%, while saying recovery depends on reliable supply chains and better execution of product launches. https://openbell.ai/news/ONCO:1793952146000 2026-11-06T08:02:26.000Z daily 0.9 https://cdn.brandfetch.io/ONCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oncopeptides AB Reports Q3 2026 Financial Results Oncopeptides AB reported Q3 2026 sales of SEK 28.5 million, up 41% year over year. Its gross margin was 98% for the first nine months of 2026. The company cited Pepaxti’s expansion into third-line treatment and glioblastoma proof-of-concept studies as growth catalysts, and continues to target positive commercial cash flow by 2027. https://openbell.ai/news/NYXH:1793952146000 2026-11-06T08:02:26.000Z daily 0.9 https://cdn.brandfetch.io/NYXH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nyxoah Reports Third Quarter 2026 Financial and Operating Results Nyxoah reported a third-quarter 2026 operating loss of €21.9 million, down from €24.4 million a year earlier, citing higher gross profit and lower R&D expenses as it focuses on commercial execution. It held €77.1 million in cash, cash equivalents and financial assets as of September 30, and reaffirmed its 2026 outlook for global net revenue of €33 million to €35 million and gross margin of 60% to 62%. U.S. revenue grew 29% sequentially. The company said ACCCESS study results and a pending PMA supplement submission could support expanding Genio’s use to patients with complete concentric collapse. https://openbell.ai/news/CCC:1793952140000 2026-11-06T08:02:20.000Z daily 0.9 https://cdn.brandfetch.io/CCC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cavotec Reports Third Quarter 2026 Financial Results Cavotec Group reported third-quarter 2026 revenue of EUR 42.6 million, up 18.9% year over year, and a record order backlog of EUR 160 million, supported by demand for shore power systems and motorized cable reels. EBIT improved to EUR 0.8 million from a loss of EUR 0.5 million a year earlier. The company said profitability remains below expectations despite higher volumes and is pursuing cost savings targeting an annual run-rate reduction of EUR 3 million by early 2027. https://openbell.ai/news/NTI:1793952140000 2026-11-06T08:02:20.000Z daily 0.9 https://cdn.brandfetch.io/NTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Norsk Titanium Reports Q3 2026 Financial Results and Strategic Outlook Norsk Titanium reported Q3 2026 revenue and other income of $2.1 million, three times the year-earlier level. It ended the quarter with $27.2 million in cash and maintained its full-year 2026 revenue forecast of approximately $8 million. The company cited aerospace, defense, and Hittech as key growth drivers and said it plans to seek additional financing to support its goal of reaching break-even by 2028. https://openbell.ai/news/AZT:1793952137000 2026-11-06T08:02:17.000Z daily 0.9 https://cdn.brandfetch.io/AZT/w/400/h/400?c=1idopYfmtR7ZKg8QMud ArcticZymes Technologies Reports Q3 2026 Financial Results ArcticZymes Technologies reported Q3 2026 revenue growth of 15% year over year, or 24% at constant currency, driven mainly by demand in its biomanufacturing and CDMO segments. Nine-month EBITDA was NOK 12.1 million. Management said recently launched RNA enzymes could provide a new growth platform, while foreign-exchange movements and timing remained headwinds. https://openbell.ai/news/ATT:1793952135000 2026-11-06T08:02:15.000Z daily 0.9 https://cdn.brandfetch.io/ATT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Grupa Azoty Reports Preliminary Q3 2026 Net Loss of 547 Million Zlotys Grupa Azoty reported a preliminary net loss of 547 million zlotys for the third quarter of 2026. The company said it will publish its full consolidated quarterly report at a later date. https://openbell.ai/news/CAT.B:1793952135000 2026-11-06T08:02:15.000Z daily 0.9 https://cdn.brandfetch.io/CAT.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud Catella AB Reports Q3 2026 Financial Results and Transformation Plan Catella AB reported Q3 2026 income of SEK 359 million, down 10% year over year, while adjusted EBIT improved to SEK 15 million. The company announced a transformation initiative targeting approximately SEK 40 million in annual efficiency gains from 2027, supported by selective investments and continued focus on revenue growth. https://openbell.ai/news/FOCL:1793952134000 2026-11-06T08:02:14.000Z daily 0.9 https://cdn.brandfetch.io/FOCL/w/400/h/400?c=1idopYfmtR7ZKg8QMud FocalTherics™ Reports Third Quarter 2026 Financial Results FocalTherics (formerly EDAP TMS S.A.) reported third-quarter 2026 revenue of $9.8 million, up 26% year over year, and gross margin of 51.4%, compared with 46.6% a year earlier. It sold seven Focal One capital systems and recorded a 32% year-over-year increase in U.S. procedure volume. The company narrowed its 2026 revenue guidance to $50 million–$52 million from $50 million–$54 million and ended the quarter with $56.3 million in cash and cash equivalents. https://openbell.ai/news/COLUM:1793952130000 2026-11-06T08:02:10.000Z daily 0.9 https://cdn.brandfetch.io/COLUM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Columbus A/S Reports Q3 2026 Financial Results Columbus A/S reported Q3 2026 revenue growth of 6%, an adjusted EBITDA margin of 10.3%, and operating cash flow of DKK 55 million. The company lowered its full-year guidance, citing restructuring costs. It also launched ASTRA 29, a strategic initiative focused on growth and profitability through an AI-enabled business model. https://openbell.ai/news/ZZ.B:1793952128000 2026-11-06T08:02:08.000Z daily 0.9 https://cdn.brandfetch.io/ZZ.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud GomSpace Reports Continued Profitable Growth in Q3 2026 GomSpace reported Q3 2026 revenue of SEK 130.4 million, up 17% year over year, and EBITDA of SEK 18.6 million, a 14% margin. Quarterly order intake more than doubled to SEK 119.7 million; year-to-date revenue rose 25% and EBITDA increased 64%. Management reaffirmed its 2030 targets of SEK 1.6 billion in annual revenue and an EBITDA margin above 20%. The article did not report a stock-price movement. https://openbell.ai/news/AKW:1793952128000 2026-11-06T08:02:08.000Z daily 0.9 https://cdn.brandfetch.io/AKW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Akwel Reports 17.4% Decline in Nine-Month Revenue Akwel reported a 17.4% decline in revenue for the first nine months of 2026. The company, which supplies components to the automotive and heavy-goods vehicle sectors, disclosed the results in regulated financial reporting. The report did not provide revenue totals, profit figures, or stock-price movements. https://openbell.ai/news/GAV:1793952127000 2026-11-06T08:02:07.000Z daily 0.9 https://cdn.brandfetch.io/GAV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Carlo Gavazzi Returns to Profitability in First Half of 2026/27 Carlo Gavazzi returned to profitability at all levels in the first half of fiscal 2026/27, recovering from a profit decline in the prior year. The report did not provide specific revenue or profit figures, growth rates, or stock-price movements. https://openbell.ai/news/GUBRA:1793952120000 2026-11-06T08:02:00.000Z daily 0.9 https://cdn.brandfetch.io/GUBRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gubra Reports Q3 2026 Earnings and Pipeline Progress Gubra reported Q3 2026 record-level earnings, supported by USD 50 million and EUR 10 million in partner milestone payments. CRO revenue grew 6%, with an EBIT margin of 25%. Two partnered obesity programs advanced to Phase 2, while GUB-UCN2 entered Phase 1/2a clinical testing. Gubra narrowed its 2026 CRO guidance to 2–6% growth and a 10–13% margin, and lowered its biotech cost guidance. https://openbell.ai/news/ADKO:1793952119000 2026-11-06T08:01:59.000Z daily 0.9 https://cdn.brandfetch.io/ADKO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raiffeisen Bank International Announces Results of Tender Offer for Addiko Bank Raiffeisen Bank International (RBI) received acceptances for 18,688,243 Addiko Bank shares, equal to 95.74% of Addiko’s current share capital, and expects to hold 18,688,557 shares after settlement. RBI said a planned carve-out of Addiko subsidiaries in Serbia, Bosnia and Herzegovina, and Montenegro now appears unlikely after Serbia’s central bank revoked Alta Banka’s banking license, so it expects to retain all subsidiaries. Settlement is expected within ten trading days after all conditions are met, which must occur by May 14, 2027. https://openbell.ai/news/BRNL:1793952117000 2026-11-06T08:01:57.000Z daily 0.9 https://cdn.brandfetch.io/BRNL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brunel International N.V. Announces Third Quarter 2026 Results Brunel International N.V. reported third-quarter 2026 revenue of EUR 301.2 million, down 1% year over year (2% organically), while gross profit was stable at EUR 56.6 million. Underlying EBIT fell 5% to EUR 11.4 million, although reported EBIT rose 43% to EUR 8.9 million. Strong profit growth in DACH, Australasia and the Americas was partly offset by weaker results in the Netherlands, the Middle East and India. Brunel is completing turnaround initiatives in the Netherlands and Belgium, aiming to improve their EBIT contribution next year. https://openbell.ai/news/HFG:1793952115000 2026-11-06T08:01:55.000Z daily 0.9 https://cdn.brandfetch.io/HFG/w/400/h/400?c=1idopYfmtR7ZKg8QMud HelloFresh Reports Q3 2026 Financial Results HelloFresh reported Q3 2026 revenue of €1.4 billion, down 9.8% year over year (11.3% at constant currency). It cut marketing spending by 24% to protect unit economics and improve profitability, affecting new customer acquisition. Adjusted EBITDA increased to €54.4 million from €40.3 million a year earlier, while Ready-to-Eat reached adjusted EBITDA break-even. The company reaffirmed 2026 guidance for a 9%–11% constant-currency revenue decline and adjusted EBITDA of €350 million–€370 million. https://openbell.ai/news/BTS.B:1793952111000 2026-11-06T08:01:51.000Z daily 0.9 https://cdn.brandfetch.io/BTS.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTS Group AB (publ) Reports Interim Results for January–September 2026 BTS Group reported record third-quarter results for 2026, with net sales of MSEK 716, up 13% adjusted for currency effects. EBITA increased 79% to MSEK 81, for an 11.4% margin, while profit after tax rose 217% to MSEK 40 and earnings per share reached SEK 2.12. Management expects full-year 2026 results to be significantly better than in 2025. https://openbell.ai/news/AMG:1793952109000 2026-11-06T08:01:49.000Z daily 0.9 https://cdn.brandfetch.io/AMG/w/400/h/400?c=1idopYfmtR7ZKg8QMud AMG Critical Materials N.V. Reports Third Quarter 2026 Results and Increases Full-Year Guidance AMG Critical Materials reported third-quarter 2026 adjusted EBITDA of $78 million, up 22% from $64 million a year earlier, driven by Brazilian lithium operations and tantalum sales. The company raised its full-year adjusted EBITDA guidance to approximately $280 million from its prior range of $230 million to $250 million, and said it expects positive free cash flow for the year. AMG ended the quarter with $550 million in total liquidity. Strategic milestones included a Frankfurt Stock Exchange listing and European Commission recognition of its lithium refinery and Zinnwald Lithium activities as Strategic Projects under the Critical Raw Materials Act. https://openbell.ai/news/PHAR:1793952108000 2026-11-06T08:01:48.000Z daily 0.9 https://cdn.brandfetch.io/PHAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud MHRA Approves Pharming's Joenja for Children with APDS in the U.K. The U.K. MHRA approved Pharming Group’s Joenja (leniolisib) for children aged 4 to 11 with APDS, expanding its existing approval for older patients. Pharming said it will work with the NHS and other stakeholders to support timely access for eligible children. The announcement did not report financial figures or a stock-price impact. https://openbell.ai/news/ICOS:1793952106000 2026-11-06T08:01:46.000Z daily 0.9 https://cdn.brandfetch.io/ICOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Intercos Reports Record Third Quarter 2026 Financial Results Intercos reported record third-quarter 2026 revenue of €294.2 million, up 13% year over year; revenue for the first nine months reached €632.7 million, up 3.5%. Nine-month adjusted EBITDA rose 1% to €117 million, while third-quarter adjusted EBITDA increased 7.5% to €44.5 million. Makeup and Hair & Body growth offset continued weakness in Western Skincare, and the company confirmed its full-year guidance, citing strong orders and expecting a strong start to 2027. Its net financial position was €140.7 million at September 30, after a €60 million contribution to shareholders during the period. https://openbell.ai/news/AKVA:1793952106000 2026-11-06T08:01:46.000Z daily 0.9 https://cdn.brandfetch.io/AKVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud AKVA group Reports Q3 2026 Financial Results AKVA group reported Q3 2026 revenue of NOK 959 million, down 14% year over year, while EBITDA rose 15% to NOK 170 million, an increase of NOK 22 million. Quarterly order intake was NOK 714 million, and the order backlog stood at NOK 2,718 million at quarter-end. The company declared a dividend of NOK 1 per share on September 22 for the second half of the year.